文献速递泌尿男性生殖肿瘤

根治性前列腺切除术后挽救治疗时前列腺特异性抗原水平与死亡风险

Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death.
PubMed 文献 · J Clin Oncol · 2023-03-01

该研究利用跨国数据库25,551例pT2-4N0或NXM0前列腺癌患者,评估根治性前列腺切除术后生化失败行挽救性放疗时PSA水平与全因死亡风险的关系。中位随访6.00年,PSA>0.25 ng/mL时启动挽救性放疗者全因死亡风险显著高于PSA≤0.25 ng/mL者(AHR 1.49;95%CI 1.11-2.00;P=0.008)。

要点

  • PSA>0.25 ng/mL时启动挽救性放疗与全因死亡风险升高相关(AHR 1.49)。
  • PSA≤0.25 ng/mL时启动挽救性放疗未显示全因死亡风险显著升高。
  • 该关联在预设的0.10至0.50 ng/mL各切点中,仅0.25 ng/mL以上切点显著。

核心结论

  • 在至多一个高危因素的患者中,PSA>0.25 ng/mL时启动挽救性放疗与全因死亡风险升高相关。

研究设计与样本

  • 跨国数据库纳入25,551例pT2-4N0或NXM0前列腺癌患者。
  • 采用多变量Cox回归分析,评估PSA切点从0.10 ng/mL起以0.05递增至0.50 ng/mL时启动挽救性放疗与全因死亡风险的关联。
  • 模型校正根治性前列腺切除术时年龄和年份、已确立的前列腺癌预后因素、机构以及雄激素剥夺治疗的时间依赖性使用。

主要发现

  • 中位随访6.00年,PSA>0.25 ng/mL时启动挽救性放疗者全因死亡风险显著高于PSA≤0.25 ng/mL者(AHR 1.49;95%CI 1.11-2.00;P=0.008)。
  • 该全因死亡风险升高在至0.50 ng/mL的所有PSA切点均显著。
  • PSA切点低于0.25 ng/mL时全因死亡风险未达统计学显著。

关键数值与推荐

  • PSA>0.25 ng/mL时启动挽救性放疗与全因死亡风险升高相关(AHR 1.49;95%CI 1.11-2.00;P=0.008)。
  • PSA≤0.25 ng/mL时启动挽救性放疗未显示全因死亡风险显著升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Both the performance characteristics of prostate-specific membrane antigen positron emission tomography and insurance approval improves with increasing prostate-specific antigen (PSA) level causing some physicians to delay post-radical prostatectomy salvage radiation therapy (sRT) after PSA failure. Yet, it is unknown for men with at most one high-risk factor (ie, pT3/4 or prostatectomy [p] Gleason score 8-10) whether a PSA level exists above which initiating sRT is associated with increased all-cause mortality (ACM)-risk and was investigated. METHODS: Using a multinational database of 25,551 patients with pT2-4N0 or NXM0 prostate cancer, multivariable Cox regression analysis evaluated whether an association with a significant increase in ACM-risk existed when sRT was delivered above a prespecified PSA level beginning at 0.10 ng/mL and in 0.05 increments up to 0.50 ng/mL versus at or below that level. The model was adjusted for age at and year of radical prostatectomy, established prostate cancer prognostic factors, institution, and the time-dependent use of androgen deprivation therapy. RESULTS: After a median follow-up of 6.00 years, patients who received sRT at a PSA level >0.25 ng/mL had a significantly higher ACM-risk (AHR, 1.49; 95% CI, 1.11 to 2.00; P = .008) compared with men who received sRT when the PSA was ≤0.25 mg/mL. This elevated ACM-risk remained significant for all PSA cutpoints up to 0.50 ng/mL but was not significant at PSA cutpoint values below 0.25 ng/mL. CONCLUSION: Among patients with at most one high-risk factor, initiating sRT above a PSA level of 0.25 ng/mL was associated with increased ACM-risk.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tilki D, Chen MH, Wu J, et al. Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. J Clin Oncol. 2023. PMID: 36857638. doi:10.1200/JCO.22.02489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。